---
title: "HAOHAI BIOTEC acquires 19.8% of Ruiji Bio for a consideration of 38.35 million RMB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/269621478.md"
description: "HAOHAI BIOTEC announced that it will acquire a 19.8% equity stake in Ruiji Biotech from an independent third party. The latter's products are mainly used in the fields of orthopedics and ophthalmology, with a cash consideration of 38.35 million RMB, which will be paid using internal resources"
datetime: "2025-12-14T09:39:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269621478.md)
  - [en](https://longbridge.com/en/news/269621478.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269621478.md)
---

# HAOHAI BIOTEC acquires 19.8% of Ruiji Bio for a consideration of 38.35 million RMB

HAOHAI BIOTEC (06826.HK) announced the acquisition of a 19.8% stake in Ruiji Biotech from an independent third party. The latter's products are mainly used in the fields of orthopedics and ophthalmology, with a cash consideration of RMB 38.35 million, which will be paid using internal resources

### Related Stocks

- [688366.CN](https://longbridge.com/en/quote/688366.CN.md)
- [06826.HK](https://longbridge.com/en/quote/06826.HK.md)

## Related News & Research

- [03:35 ETNew Publication Further Validates Capitainer Technology for Remote Alzheimer's Disease Biomarker Testing](https://longbridge.com/en/news/287177100.md)
- [Lexitas Pharma Services, a Leading Ophthalmology CRO, Announces the Acquisition of Erie Retina Research, CASExERIE and Element Erie](https://longbridge.com/en/news/286907835.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [VN introduces biometric authentication for e-invoice procedures](https://longbridge.com/en/news/287182852.md)
- [Nanjing Leads Biolabs Wins Phase III Green Light for Key Cancer Drug Opamtistomig](https://longbridge.com/en/news/286828874.md)